دورية أكاديمية
B-cell infiltration is associated with survival outcomes following programmed cell death protein 1 inhibition in head and neck squamous cell carcinoma.
| العنوان: | B-cell infiltration is associated with survival outcomes following programmed cell death protein 1 inhibition in head and neck squamous cell carcinoma. |
|---|---|
| المؤلفون: | Gavrielatou N; Department of Internal Medicine, Section of Medical Oncology, Attikon University Hospital, National Kapodistrian University of Athens, Athens, Greece; Department of Pathology, Yale University School of Medicine, New Haven, USA., Fortis E; Ludwig Institute for Cancer Research, University Hospital of Lausanne (CHUV), Lausanne, Switzerland., Spathis A; Department of Pathology, Attikon University Hospital, National Kapodistrian University of Athens, Athens, Greece., Anastasiou M; Department of Internal Medicine, Section of Medical Oncology, Attikon University Hospital, National Kapodistrian University of Athens, Athens, Greece., Economopoulou P; Department of Internal Medicine, Section of Medical Oncology, Attikon University Hospital, National Kapodistrian University of Athens, Athens, Greece., Foukas GRP; Department of Pathology, Attikon University Hospital, National Kapodistrian University of Athens, Athens, Greece., Lelegiannis IM; Department of Internal Medicine, Section of Medical Oncology, Attikon University Hospital, National Kapodistrian University of Athens, Athens, Greece., Rusakiewicz S; Ludwig Institute for Cancer Research, University Hospital of Lausanne (CHUV), Lausanne, Switzerland., Vathiotis I; Department of Pathology, Yale University School of Medicine, New Haven, USA., Aung TN; Department of Pathology, Yale University School of Medicine, New Haven, USA., Tissot S; Ludwig Institute for Cancer Research, University Hospital of Lausanne (CHUV), Lausanne, Switzerland., Kastrinou A; Department of Internal Medicine, Section of Medical Oncology, Attikon University Hospital, National Kapodistrian University of Athens, Athens, Greece., Kotsantis I; Department of Internal Medicine, Section of Medical Oncology, Attikon University Hospital, National Kapodistrian University of Athens, Athens, Greece., Vagia EM; Department of Internal Medicine, Section of Medical Oncology, Attikon University Hospital, National Kapodistrian University of Athens, Athens, Greece., Panayiotides I; Department of Pathology, Attikon University Hospital, National Kapodistrian University of Athens, Athens, Greece., Rimm DL; Department of Pathology, Yale University School of Medicine, New Haven, USA., Coukos G; Ludwig Institute for Cancer Research, University Hospital of Lausanne (CHUV), Lausanne, Switzerland., Homicsko K; Ludwig Institute for Cancer Research, University Hospital of Lausanne (CHUV), Lausanne, Switzerland., Foukas P; Department of Pathology, Attikon University Hospital, National Kapodistrian University of Athens, Athens, Greece., Psyrri A; Department of Internal Medicine, Section of Medical Oncology, Attikon University Hospital, National Kapodistrian University of Athens, Athens, Greece. Electronic address: dpsyrri@med.uoa.gr. |
| المصدر: | Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2024 Apr; Vol. 35 (4), pp. 340-350. Date of Electronic Publication: 2023 Dec 28. |
| نوع المنشور: | Clinical Trial; Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Country of Publication: England NLM ID: 9007735 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1569-8041 (Electronic) Linking ISSN: 09237534 NLM ISO Abbreviation: Ann Oncol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2020- : London : Elsevier Original Publication: Dordrecht ; Boston : Kluwer Academic Publishers, c1990- |
| مواضيع طبية MeSH: | Head and Neck Neoplasms*/drug therapy , Head and Neck Neoplasms*/genetics , Nivolumab*/therapeutic use, Humans ; B7-H1 Antigen ; Programmed Cell Death 1 Receptor ; Prospective Studies ; Squamous Cell Carcinoma of Head and Neck/drug therapy ; Tumor Microenvironment |
| مستخلص: | Background: Programmed cell death protein 1 (PD-1) axis blockade has become the mainstay in the treatment of recurrent and/or metastatic (R/M) head and neck squamous cell cancer (HNSCC). Programmed death-ligand 1 (PD-L1) is the only approved biomarker for patient selection; however, response rate is limited even among high expressors. Our primary objective was to investigate the association of immune cell-related biomarkers in the tumor and tumor microenvironment with PD-1 checkpoint inhibitors' outcomes in patients with R/M HNSCC. Patients and Methods: NCT03652142 was a prospective study in nivolumab-treated platinum-refractory R/M HNSCC, aiming to evaluate biomarkers of response to treatment. Tumor biopsies and blood samples were collected from 60 patients at baseline, post-treatment, and at progression. Immune cells in the tumor and stromal compartments were quantified by immunofluorescence using a five-protein panel (CD3, CD8, CD20, FoxP3, cytokeratin). Tertiary lymphoid structures (TLSs), PD-L1 expression, and peripheral blood immune cell composition were also evaluated for associations with outcome. Our findings were validated by gene set enrichment analysis (GSEA) messenger RNA in situ expression data from the same patients, for B-cell- and TLS-associated genes. Results: High pre-treatment density of stromal B cells was associated with prolonged progression-free survival (PFS) (P = 0.011). This result was validated by GSEA, as stromal enrichment with B-cell-associated genes showed association with response to nivolumab. PD-L1 positivity combined with high B-cell counts in stroma defined a subgroup with significantly longer PFS and overall survival (P = 0.013 and P = 0.0028, respectively). Conclusions: Increased B cells in pre-treatment HNSCC biopsy samples correlate with prolonged benefit from PD-1-based immunotherapy and could further enhance the predictive value of PD-L1 expression. Competing Interests: Disclosure AP has served as an advisor for MSD, Nanobiotics, BMS, Astrazeneca, Merck Serono. She has received institutional research funding from BMS, Merck Serono, Roche, Sanofi. DLR has served as an advisor for Astra Zeneca, Agendia, Amgen, BMS, Cell Signaling Technology, Cepheid, Danaher, Daiichi Sankyo, Genoptix/Novartis, GSK, Konica Minolta, Merck, NanoString, PAIGE.AI, Perkin Elmer, Roche, Sanofi, and Ventana. Amgen, Cepheid, NavigateBP, NextCure, and Konica Minolta fund research in DLR’s lab. All other authors have declared no conflicts of interest. (Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved.) |
| فهرسة مساهمة: | Keywords: B lymphocytes; head and neck neoplasms; immunotherapy; lymphocytes; programmed cell death 1 receptor; tumor infiltrating |
| المشرفين على المادة: | 0 (B7-H1 Antigen) 31YO63LBSN (Nivolumab) 0 (Programmed Cell Death 1 Receptor) |
| تواريخ الأحداث: | Date Created: 20231230 Date Completed: 20240408 Latest Revision: 20240415 |
| رمز التحديث: | 20240416 |
| DOI: | 10.1016/j.annonc.2023.12.011 |
| PMID: | 38159908 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1569-8041 |
|---|---|
| DOI: | 10.1016/j.annonc.2023.12.011 |